BSS-Et

Overview

BSS-Et is a near-infrared phototheranostic agent that serves as one of the two release units of hypoxia-responsive prodrug BNNC, responsible for generating photodynamic therapy (PDT) and photothermal therapy (PTT) effects at tumor sites. BSS-Et produces reactive oxygen species and singlet oxygen upon irradiation, inducing oxidative stress and DNA damage. When combined with (R)-CR8 ( HY-18340 ), BSS-Et enhances DNA damage and apoptosis in breast cancer cells. BSS-Et can be used in breast cancer-related research.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Photosensitizer | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > DNA/RNA Synthesis

Product Information

• Catalog No.: HY-184451
• CAS No.: 2825003-94-7
• Molecular Formula: C33H31ClN4O3
• Molecular Weight: 567.08
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source